Tobin Schilke - 31 Dec 2021 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Terri McDowell, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Dec 2021
Net transactions value
+$5,604
Form type
4
Filing time
04 Jan 2022, 19:58:29 UTC
Previous filing
17 Dec 2021
Next filing
04 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Other $5,604 +404 +0.6% $13.87 68,056 31 Dec 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31,2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).